Challenges in Biomaterial-Based Drug Delivery Approach for the Treatment of Neurodegenerative Diseases: Opportunities for Extracellular Vesicles
Abstract
:1. Introduction
2. Challenges and Implications of Biomaterials-Based Drug Delivery Approach in Neurodegenerative Diseases
3. Extracellular Vesicle-Based Drug Delivery Systems
3.1. EV Background
3.2. Drug Loading in EVs
3.2.1. Endogenous Drug Loading
3.2.2. Exogenous Drug Loading
3.3. EV-Based Drug Delivery for Neurodegenerative Diseases
3.3.1. AD
3.3.2. PD
3.3.3. MS
3.3.4. HAND
3.3.5. TBI
3.3.6. COVID-19 Associated Brain Damage
3.4. EV-Based Therapeutic Approach
4. Limitations of EV-Based Drug Delivery Systems and Current Advancements to Counter these Limitations
4.1. Interaction of Drugs with EV Components
4.2. In Vivo Pharmacokinetics of EV Drugs
4.2.1. Intravenous Injection (IV)
4.2.2. Intraperitoneal Injections, Subcutaneous Injections, and Oral Administration
4.3. Delivery of Drugs to the Target
4.4. Immune Clearance
5. Conclusions
Funding
Acknowledgments
Conflicts of Interest
References
- Dugger, B.N.; Dickson, D.W. Pathology of neurodegenerative diseases. Cold Spring Harb. Perspect. Biol. 2017, 9. [Google Scholar] [CrossRef] [PubMed]
- Jung, Y.J.; Tweedie, D.; Scerba, M.T.; Greig, N.H. Neuroinflammation as a factor of neurodegenerative disease: Thalidomide analogs as treatments. Front. Cell Dev. Biol. 2019, 7, 313. [Google Scholar] [CrossRef] [PubMed]
- Stephenson, J.; Nutma, E.; van der Valk, P.; Amor, S. Inflammation in CNS neurodegenerative diseases. Immunology 2018, 154, 204–219. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Maher, P. The potential of flavonoids for the treatment of neurodegenerative diseases. Int. J. Mol. Sci. 2019, 20, 3056. [Google Scholar] [CrossRef] [Green Version]
- Gong, Y.; Zhi, K.; Nagesh, P.K.B.; Sinha, N.; Chowdhury, P.; Chen, H.; Gorantla, S.; Yallapu, M.M.; Kumar, S. An elvitegravir nanoformulation crosses the blood–brain barrier and suppresses HIV-1 replication in Microglia. Viruses 2020, 12, 564. [Google Scholar] [CrossRef]
- Gong, Y.; Chowdhury, P.; Nagesh, P.K.B.; Rahman, M.A.; Zhi, K.; Yallapu, M.M.; Kumar, S. Novel elvitegravir nanoformulation for drug delivery across the blood-brain barrier to achieve HIV-1 suppression in the CNS macrophages. Sci. Rep. 2020, 10, 3835. [Google Scholar] [CrossRef] [Green Version]
- Ramanathan, S.; Archunan, G.; Sivakumar, M.; Tamil Selvan, S.; Fred, A.L.; Kumar, S.; Gulyás, B.; Padmanabhan, P. Theranostic applications of nanoparticles in neurodegenerative disorders. Int. J. Nanomed. 2018, 13, 5561–5576. [Google Scholar] [CrossRef] [Green Version]
- Li, Y.; Liu, R.; Ji, W.; Li, Y.; Liu, L.; Zhang, X. Delivery systems for theranostics in neurodegenerative diseases. Nano Res. 2018, 11, 5535–5555. [Google Scholar] [CrossRef]
- Vissers, C.; Ming, G.-L.; Song, H. Nanoparticle technology and stem cell therapy team up against neurodegenerative disorders. Adv. Drug Deliv. Rev. 2019, 148, 239–251. [Google Scholar] [CrossRef]
- Jain, A.; Kim, Y.-T.; McKeon, R.J.; Bellamkonda, R.V. In situ gelling hydrogels for conformal repair of spinal cord defects, and local delivery of BDNF after spinal cord injury. Biomaterials 2006, 27, 497–504. [Google Scholar] [CrossRef]
- Fon, D.; Al-Abboodi, A.; Chan, P.P.Y.; Zhou, K.; Crack, P.; Finkelstein, D.I.; Forsythe, J.S. Effects of GDNF-loaded injectable gelatin-based hydrogels on endogenous neural progenitor cell migration. Adv. Healthc. Mater. 2014, 3, 761–774. [Google Scholar] [CrossRef] [PubMed]
- Kim, T.; Lee, N.; Arifin, D.R.; Shats, I.; Janowski, M.; Walczak, P.; Hyeon, T.; Bulte, J.W.M. In vivo micro-CT imaging of human mesenchymal stem cells labeled with gold-poly-L-lysine nanocomplexes. Adv. Funct. Mater. 2017, 27. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sintov, A.C.; Velasco-Aguirre, C.; Gallardo-Toledo, E.; Araya, E.; Kogan, M.J. Metal nanoparticles as targeted carriers circumventing the blood-brain barrier. Int. Rev. Neurobiol. 2016, 130, 199–227. [Google Scholar] [CrossRef] [PubMed]
- Gonzalez-Carter, D.A.; Leo, B.F.; Ruenraroengsak, P.; Chen, S.; Goode, A.E.; Theodorou, I.G.; Chung, K.F.; Carzaniga, R.; Shaffer, M.S.P.; Dexter, D.T.; et al. Silver nanoparticles reduce brain inflammation and related neurotoxicity through induction of H2S-synthesizing enzymes. Sci. Rep. 2017, 7, 42871. [Google Scholar] [CrossRef] [Green Version]
- Kong, S.D.; Lee, J.; Ramachandran, S.; Eliceiri, B.P.; Shubayev, V.I.; Lal, R.; Jin, S. Magnetic targeting of nanoparticles across the intact blood-brain barrier. J. Control. Release Off. J. Control. Release Soc. 2012, 164, 49–57. [Google Scholar] [CrossRef] [Green Version]
- Niu, S.; Zhang, L.-K.; Zhang, L.; Zhuang, S.; Zhan, X.; Chen, W.-Y.; Du, S.; Yin, L.; You, R.; Li, C.-H.; et al. Inhibition by multifunctional magnetic nanoparticles loaded with alpha-synuclein RNAi plasmid in a Parkinson’s disease model. Theranostics 2017, 7, 344–356. [Google Scholar] [CrossRef] [Green Version]
- Asati, A.; Santra, S.; Kaittanis, C.; Nath, S.; Perez, J.M. Oxidase-like activity of polymer-coated cerium oxide nanoparticles. Angew. Chem. 2009, 48, 2308–2312. [Google Scholar] [CrossRef]
- Hirst, S.M.; Karakoti, A.S.; Tyler, R.D.; Sriranganathan, N.; Seal, S.; Reilly, C.M. Anti-inflammatory properties of cerium oxide nanoparticles. Small 2009, 5, 2848–2856. [Google Scholar] [CrossRef]
- Król, A.; Pomastowski, P.; Rafińska, K.; Railean-Plugaru, V.; Buszewski, B. Zinc oxide nanoparticles: Synthesis, antiseptic activity and toxicity mechanism. Adv. Colloid Interface Sci. 2017, 249, 37–52. [Google Scholar] [CrossRef]
- Sirelkhatim, A.; Mahmud, S.; Seeni, A.; Kaus, N.H.M.; Ann, L.C.; Bakhori, S.K.M.; Hasan, H.; Mohamad, D. Review on Zinc oxide nanoparticles: Antibacterial activity and toxicity mechanism. Nano-Micro Lett. 2015, 7, 219–242. [Google Scholar] [CrossRef] [Green Version]
- Tokuraku, K.; Marquardt, M.; Ikezu, T. Real-time imaging and quantification of amyloid-beta peptide aggregates by novel quantum-dot nanoprobes. PLoS ONE 2009, 4, e8492. [Google Scholar] [CrossRef] [PubMed]
- Agarwal, R.; Domowicz, M.S.; Schwartz, N.B.; Henry, J.; Medintz, I.; Delehanty, J.B.; Stewart, M.H.; Susumu, K.; Huston, A.L.; Deschamps, J.R.; et al. Delivery and tracking of quantum dot peptide bioconjugates in an intact developing avian brain. ACS Chem. Neurosci. 2015, 6, 494–504. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Barandeh, F.; Nguyen, P.-L.; Kumar, R.; Iacobucci, G.J.; Kuznicki, M.L.; Kosterman, A.; Bergey, E.J.; Prasad, P.N.; Gunawardena, S. Organically modified silica nanoparticles are biocompatible and can be targeted to neurons in vivo. PLoS ONE 2012, 7, e29424. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liu, D.; Lin, B.; Shao, W.; Zhu, Z.; Ji, T.; Yang, C. In vitro and in vivo studies on the transport of PEGylated silica nanoparticles across the blood-brain barrier. ACS Appl. Mater. Interfaces 2014, 6, 2131–2136. [Google Scholar] [CrossRef] [PubMed]
- Jampilek, J.; Zaruba, K.; Oravec, M.; Kunes, M.; Babula, P.; Ulbrich, P.; Brezaniova, I.; Opatrilova, R.; Triska, J.; Suchy, P. Preparation of silica nanoparticles loaded with nootropics and their in vivo permeation through blood-brain barrier. Biomed. Res. Int. 2015, 2015, 812673. [Google Scholar] [CrossRef] [Green Version]
- Kohli, A.G.; Kierstead, P.H.; Venditto, V.J.; Walsh, C.L.; Szoka, F.C. Designer lipids for drug delivery: From heads to tails. J. Control. Release Off. J. Control. Release Soc. 2014, 190, 274–287. [Google Scholar] [CrossRef] [Green Version]
- Tam, V.H.; Sosa, C.; Liu, R.; Yao, N.; Priestley, R.D. Nanomedicine as a non-invasive strategy for drug delivery across the blood brain barrier. Int. J. Pharm. 2016, 515, 331–342. [Google Scholar] [CrossRef]
- Schiborr, C.; Kocher, A.; Behnam, D.; Jandasek, J.; Toelstede, S.; Frank, J. The oral bioavailability of curcumin from micronized powder and liquid micelles is significantly increased in healthy humans and differs between sexes. Mol. Nutr. Food Res. 2014, 58, 516–527. [Google Scholar] [CrossRef]
- Mehnert, W.; Mäder, K. Solid lipid nanoparticles: Production, characterization and applications. Adv. Drug Deliv. Rev. 2001, 47, 165–196. [Google Scholar] [CrossRef]
- Kumar, S.; Zhi, K.; Mukherji, A.; Gerth, K. Repurposing antiviral protease inhibitors using extracellular vesicles for potential therapy of COVID-19. Viruses 2020, 12, 486. [Google Scholar] [CrossRef]
- Xiong, X.Y.; Tam, K.C.; Gan, L.H. Release kinetics of hydrophobic and hydrophilic model drugs from pluronic F127/poly (lactic acid) nanoparticles. J. Control. Release Off. J. Control. Release Soc. 2005, 103, 73–82. [Google Scholar] [CrossRef] [PubMed]
- Pelaz, B.; del Pino, P.; Maffre, P.; Hartmann, R.; Gallego, M.; Rivera-Fernández, S.; de la Fuente, J.M.; Nienhaus, G.U.; Parak, W.J. Surface functionalization of nanoparticles with Polyethylene Glycol: Effects on protein adsorption and cellular uptake. ACS Nano 2015, 9, 6996–7008. [Google Scholar] [CrossRef] [PubMed]
- Tekade, R.K.; Maheshwari, R.; Tekade, M.; Chougule, M.B. Solid lipid nanoparticles for targeting and delivery of drugs and genes. In Nanotechnology-Based Approaches for Targeting and Delivery of Drugs and Genes; Elsevier: Cambridge, MA, USA, 2017; pp. 256–286. ISBN 978-0-12-809717-5. [Google Scholar]
- Liberti, L.; Breckenridge, A.; Hoekman, J.; Leufkens, H.; Lumpkin, M.; McAuslane, N.; Stolk, P.; Zhi, K.; Rägo, L. Accelerating access to new medicines: Current status of facilitated regulatory pathways used by emerging regulatory authorities. J. Public Health Policy 2016, 37, 315–333. [Google Scholar] [CrossRef] [PubMed]
- Liberti, L.; Breckenridge, A.; Hoekman, J.; Leufkens, H.G.; Lumpkin, M.M.; Mcauslane, N.; Stolk, P.; Zhi, K.; Rago, L. Practical aspects of developing, implementing and using facilitated regulatory pathways in the emerging markets. In Proceedings of the Poster Drug Information Association Annual Meeting, Philadelphia, PA, USA, 28 June 2016. [Google Scholar]
- Zhi, K.; Kumar, A.; Raji, B.; Kochat, H.; Kumar, S. Formulation, manufacturing and regulatory strategies for extracellular vesicles-based drug products for targeted therapy of central nervous system diseases. Expert Rev. Precis. Med. Drug Dev. 2020, 1–13. [Google Scholar] [CrossRef]
- Calzoni, E.; Cesaretti, A.; Polchi, A.; Di Michele, A.; Tancini, B.; Emiliani, C. Biocompatible polymer nanoparticles for drug delivery applications in cancer and neurodegenerative disorder therapies. J. Funct. Biomater. 2019, 10, 4. [Google Scholar] [CrossRef] [Green Version]
- Geldenhuys, W.; Mbimba, T.; Bui, T.; Harrison, K.; Sutariya, V. Brain-targeted delivery of paclitaxel using glutathione-coated nanoparticles for brain cancers. J. Drug Target. 2011, 19, 837–845. [Google Scholar] [CrossRef]
- Tosi, G.; Costantino, L.; Rivasi, F.; Ruozi, B.; Leo, E.; Vergoni, A.V.; Tacchi, R.; Bertolini, A.; Vandelli, M.A.; Forni, F. Targeting the central nervous system: In vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123. J. Control. Release Off. J. Control. Release Soc. 2007, 122, 1–9. [Google Scholar] [CrossRef]
- Vimbela, G.V.; Ngo, S.M.; Fraze, C.; Yang, L.; Stout, D.A. Antibacterial properties and toxicity from metallic nanomaterials. Int. J. Nanomed. 2017, 12, 3941–3965. [Google Scholar] [CrossRef] [Green Version]
- Mishra, A.R.; Zheng, J.; Tang, X.; Goering, P.L. Silver nanoparticle-induced Autophagic-Lysosomal disruption and NLRP3-inflammasome activation in HepG2 cells is size-dependent. Toxicol. Sci. Off. J. Soc. Toxicol. 2016, 150, 473–487. [Google Scholar] [CrossRef]
- Petters, C.; Irrsack, E.; Koch, M.; Dringen, R. Uptake and metabolism of iron oxide nanoparticles in brain cells. Neurochem. Res. 2014, 39, 1648–1660. [Google Scholar] [CrossRef]
- Zeman, T.; Loh, E.-W.; Čierný, D.; Šerý, O. Penetration, distribution and brain toxicity of titanium nanoparticles in rodents’ body: A review. IET Nanobiotechnol. 2018, 12, 695–700. [Google Scholar] [CrossRef]
- Wu, J.; Wang, C.; Sun, J.; Xue, Y. Neurotoxicity of silica nanoparticles: Brain localization and dopaminergic neurons damage pathways. ACS Nano 2011, 5, 4476–4489. [Google Scholar] [CrossRef]
- Block, M.L.; Zecca, L.; Hong, J.-S. Microglia-mediated neurotoxicity: Uncovering the molecular mechanisms. Nat. Rev. Neurosci. 2007, 8, 57–69. [Google Scholar] [CrossRef]
- Bakalova, R.; Ohba, H.; Zhelev, Z.; Ishikawa, M.; Baba, Y. Quantum dots as photosensitizers? Nat. Biotechnol. 2004, 22, 1360–1361. [Google Scholar] [CrossRef]
- Yaghini, E.; Seifalian, A.M.; MacRobert, A.J. Quantum dots and their potential biomedical applications in photosensitization for photodynamic therapy. Nanomedicine 2009, 4, 353–363. [Google Scholar] [CrossRef]
- Zhou, Z.; Song, J.; Nie, L.; Chen, X. Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy. Chem. Soc. Rev. 2016, 45, 6597–6626. [Google Scholar] [CrossRef] [Green Version]
- Martins, S.; Sarmento, B.; Ferreira, D.C.; Souto, E.B. Lipid-based colloidal carriers for peptide and protein delivery--liposomes versus lipid nanoparticles. Int. J. Nanomed. 2007, 2, 595–607. [Google Scholar]
- Armstrong, D.; Wildman, D.E. Extracellular vesicles and the promise of continuous liquid biopsies. J. Pathol. Transl. Med. 2018, 52, 1–8. [Google Scholar] [CrossRef] [Green Version]
- Li, X.; Corbett, A.L.; Taatizadeh, E.; Tasnim, N.; Little, J.P.; Garnis, C.; Daugaard, M.; Guns, E.; Hoorfar, M.; Li, I.T.S. Challenges and opportunities in exosome research-Perspectives from biology, engineering, and cancer therapy. Apl. Bioeng. 2019, 3, 011503. [Google Scholar] [CrossRef] [Green Version]
- Yamamoto, T.; Kosaka, N.; Ochiya, T. Latest advances in extracellular vesicles: From bench to bedside. Sci. Technol. Adv. Mater. 2019, 20, 746–757. [Google Scholar] [CrossRef] [Green Version]
- Kumar, A.; Stoica, B.A.; Loane, D.J.; Yang, M.; Abulwerdi, G.; Khan, N.; Kumar, A.; Thom, S.R.; Faden, A.I. Microglial-derived microparticles mediate neuroinflammation after traumatic brain injury. J. Neuroinflamm. 2017, 14, 47. [Google Scholar] [CrossRef] [Green Version]
- Valadi, H.; Ekström, K.; Bossios, A.; Sjöstrand, M.; Lee, J.J.; Lötvall, J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 2007, 9, 654–659. [Google Scholar] [CrossRef] [Green Version]
- Somiya, M. Where does the cargo go?: Solutions to provide experimental support for the “extracellular vesicle cargo transfer hypothesis”. J. Cell Commun. Signal. 2020, 14, 135–146. [Google Scholar] [CrossRef]
- Vader, P.; Breakefield, X.O.; Wood, M.J.A. Extracellular vesicles: Emerging targets for cancer therapy. Trends Mol. Med. 2014, 20, 385–393. [Google Scholar] [CrossRef] [Green Version]
- Devhare, P.B.; Ray, R.B. Extracellular vesicles: Novel mediator for cell to cell communications in liver pathogenesis. Mol. Asp. Med. 2018, 60, 115–122. [Google Scholar] [CrossRef]
- Wendler, F.; Stamp, G.W.; Giamas, G. Tumor-stromal cell communication: Small vesicles signal big changes. Trends Cancer 2016, 2, 326–329. [Google Scholar] [CrossRef] [Green Version]
- Yáñez-Mó, M.; Siljander, P.R.-M.; Andreu, Z.; Bedina Zavec, A.; Borràs, F.E.; Buzas, E.I.; Buzas, K.; Casal, E.; Cappello, F.; Carvalho, J.; et al. Biological properties of extracellular vesicles and their physiological functions. J. Extracell. Vesicles 2015, 4, 27066. [Google Scholar] [CrossRef] [Green Version]
- Petrovčíková, E.; Vičíková, K.; Leksa, V. Extracellular vesicles–biogenesis, composition, function, uptake and therapeutic applications. Biologia 2018, 73, 437–448. [Google Scholar] [CrossRef]
- Kumar, A.; Kodidela, S.; Tadrous, E.; Cory, T.J.; Walker, C.M.; Smith, A.M.; Mukherjee, A.; Kumar, S. Extracellular vesicles in viral replication and pathogenesis and their potential role in therapeutic intervention. Viruses 2020, 12, 887. [Google Scholar] [CrossRef]
- Doyle, L.; Wang, M. Overview of extracellular vesicles, their origin, composition, purpose, and methods for Exosome isolation and analysis. Cells 2019, 8, 727. [Google Scholar] [CrossRef] [Green Version]
- Patel, G.K.; Khan, M.A.; Zubair, H.; Srivastava, S.K.; Khushman, M.; Singh, S.; Singh, A.P. Comparative analysis of exosome isolation methods using culture supernatant for optimum yield, purity and downstream applications. Sci. Rep. 2019, 9, 5335. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zocco, D.; Ferruzzi, P.; Cappello, F.; Kuo, W.P.; Fais, S. Extracellular vesicles as shuttles of tumor biomarkers and anti-tumor drugs. Front. Oncol. 2014, 4. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Harding, C.V.; Heuser, J.E.; Stahl, P.D. Exosomes: Looking back three decades and into the future. J. Cell Biol. 2013, 200, 367–371. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- White, I.J.; Bailey, L.M.; Aghakhani, M.R.; Moss, S.E.; Futter, C.E. EGF stimulates annexin 1-dependent inward vesiculation in a multivesicular endosome subpopulation. EMBO J. 2006, 25, 1–12. [Google Scholar] [CrossRef] [Green Version]
- Gustafson, D.; Veitch, S.; Fish, J.E. Extracellular vesicles as protagonists of diabetic cardiovascular pathology. Front. Cardiovasc Med. 2017, 4, 71. [Google Scholar] [CrossRef] [Green Version]
- Elmore, S. Apoptosis: A review of programmed cell death. Toxicol. Pathol. 2007, 35, 495–516. [Google Scholar] [CrossRef]
- Busatto, S.; Vilanilam, G.; Ticer, T.; Lin, W.-L.; Dickson, D.W.; Shapiro, S.; Bergese, P.; Wolfram, J. Tangential flow filtration for highly efficient concentration of extracellular vesicles from large volumes of fluid. Cells 2018, 7, 273. [Google Scholar] [CrossRef] [Green Version]
- Zhang, J.; Nguyen, L.T.; Hickey, R.; Walters, N.; Palmer, A.F.; Reátegui, E. Immunomagnetic Sequential Ultrafiltration (iSUF) platform for enrichment and purification of extracellular vesicles from biofluids. bioRxiv 2020. [Google Scholar] [CrossRef]
- Tian, Y.; Gong, M.; Hu, Y.; Liu, H.; Zhang, W.; Zhang, M.; Hu, X.; Aubert, D.; Zhu, S.; Wu, L.; et al. Quality and efficiency assessment of six extracellular vesicle isolation methods by nano-flow cytometry. J. Extracell. Vesicles 2020, 9, 1697028. [Google Scholar] [CrossRef]
- Corso, G.; Mäger, I.; Lee, Y.; Görgens, A.; Bultema, J.; Giebel, B.; Wood, M.J.A.; Nordin, J.Z.; Andaloussi, S.E. Reproducible and scalable purification of extracellular vesicles using combined bind-elute and size exclusion chromatography. Sci. Rep. 2017, 7, 11561. [Google Scholar] [CrossRef]
- DeMarino, C.; Pleet, M.L.; Cowen, M.; Barclay, R.A.; Akpamagbo, Y.; Erickson, J.; Ndembi, N.; Charurat, M.; Jumare, J.; Bwala, S.; et al. Antiretroviral drugs alter the content of extracellular vesicles from HIV-1-Infected cells. Sci. Rep. 2018, 8, 7653. [Google Scholar] [CrossRef] [PubMed]
- Li, K.; Wong, D.K.; Hong, K.Y.; Raffai, R.L. Cushioned-density gradient ultracentrifugation (C-DGUC): A refined and high performance method for the isolation, characterization, and use of exosomes. Methods Mol. Biol. 2018, 1740, 69–83. [Google Scholar] [CrossRef] [PubMed]
- Szatanek, R.; Baran, J.; Siedlar, M.; Baj-Krzyworzeka, M. Isolation of extracellular vesicles: Determining the correct approach (Review). Int. J. Mol. Med. 2015, 36, 11–17. [Google Scholar] [CrossRef] [Green Version]
- Balachandran, B.; Yuana, Y. Extracellular vesicles-based drug delivery system for cancer treatment. Cogent. Med. 2019, 6. [Google Scholar] [CrossRef]
- Yang, N.J.; Hinner, M.J. Getting across the cell membrane: An overview for small molecules, peptides, and proteins. Methods Mol. Biol. 2015, 1266, 29–53. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Luan, X.; Sansanaphongpricha, K.; Myers, I.; Chen, H.; Yuan, H.; Sun, D. Engineering exosomes as refined biological nanoplatforms for drug delivery. Acta Pharm. Sin. 2017, 38, 754–763. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, L.; Zhang, L.; Knez, M. Comparison of two endogenous delivery agents in cancer therapy: Exosomes and ferritin. Pharmacol. Res. 2016, 110, 1–9. [Google Scholar] [CrossRef]
- Ren, J.; He, W.; Zheng, L.; Duan, H. From structures to functions: Insights into exosomes as promising drug delivery vehicles. Biomater. Sci. 2016, 4, 910–921. [Google Scholar] [CrossRef]
- Liu, C.; Su, C. Design strategies and application progress of therapeutic exosomes. Theranostics 2019, 9, 1015–1028. [Google Scholar] [CrossRef]
- Li, Y.; Zhang, Y.; Li, Z.; Zhou, K.; Feng, N. Exosomes as carriers for antitumor therapy. Acs Biomater. Sci. Eng. 2019, 5, 4870–4881. [Google Scholar] [CrossRef]
- Fu, S.; Wang, Y.; Xia, X.; Zheng, J.C. Exosome engineering: Current progress in cargo loading and targeted delivery. NanoImpact 2020, 20, 100261. [Google Scholar] [CrossRef]
- Xu, M.; Yang, Q.; Sun, X.; Wang, Y. Recent advancements in the loading and modification of therapeutic exosomes. Front. Bioeng. Biotechnol. 2020, 8, 586130. [Google Scholar] [CrossRef] [PubMed]
- Meng, W.; He, C.; Hao, Y.; Wang, L.; Li, L.; Zhu, G. Prospects and challenges of extracellular vesicle-based drug delivery system: Considering cell source. Drug Deliv. 2020, 27, 585–598. [Google Scholar] [CrossRef] [Green Version]
- Baek, G.; Choi, H.; Kim, Y.; Lee, H.; Choi, C. Mesenchymal stem cell-derived extracellular vesicles as therapeutics and as a drug delivery platform. Stem Cells Transl. Med. 2019, sctm.18-0226. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fuhrmann, G.; Serio, A.; Mazo, M.; Nair, R.; Stevens, M.M. Active loading into extracellular vesicles significantly improves the cellular uptake and photodynamic effect of porphyrins. J. Control. Release 2015, 205, 35–44. [Google Scholar] [CrossRef]
- Kodidela, S.; Gerth, K.; Haque, S.; Gong, Y.; Ismael, S.; Singh, A.; Tauheed, I.; Kumar, S. Extracellular vesicles: A possible link between HIV and Alzheimer’s disease-like pathology in HIV subjects? Cells 2019, 8, 968. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, Z.; Liu, T.; Yang, N.; Han, D.; Mi, X.; Li, Y.; Liu, K.; Vuylsteke, A.; Xiang, H.; Guo, X. Neurological manifestations of patients with COVID-19: Potential routes of SARS-CoV-2 neuroinvasion from the periphery to the brain. Front. Med. 2020. [Google Scholar] [CrossRef]
- Dong, X. Current strategies for brain drug delivery. Theranostics 2018, 8, 1481–1493. [Google Scholar] [CrossRef]
- Marshall, M. How COVID-19 can damage the brain. Nature 2020, 585, 342–343. [Google Scholar] [CrossRef]
- Vella, L.J.; Hill, A.F.; Cheng, L. Focus on extracellular vesicles: Exosomes and their role in protein trafficking and biomarker potential in Alzheimer’s and Parkinson’s disease. Int. J. Mol. Sci. 2016, 17, 173. [Google Scholar] [CrossRef]
- Chen, J.-J.; Zhao, B.; Zhao, J.; Li, S. Potential roles of exosomal MicroRNAs as diagnostic biomarkers and therapeutic application in Alzheimer’s disease. Neural Plast. 2017, 2017, 7027380. [Google Scholar] [CrossRef] [PubMed]
- Weller, J.; Budson, A. Current understanding of Alzheimer’s disease diagnosis and treatment. F1000Research 2018, 7. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ciregia, F.; Urbani, A.; Palmisano, G. Extracellular vesicles in brain tumors and neurodegenerative diseases. Front. Mol. Neurosci. 2017, 10, 276. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Goetzl, E.J.; Boxer, A.; Schwartz, J.B.; Abner, E.L.; Petersen, R.C.; Miller, B.L.; Carlson, O.D.; Mustapic, M.; Kapogiannis, D. Low neural exosomal levels of cellular survival factors in Alzheimer’s disease. Ann. Clin. Transl. Neurol. 2015, 2, 769–773. [Google Scholar] [CrossRef]
- Hill, A.F. Extracellular vesicles and neurodegenerative diseases. J. Neurosci. 2019, 39, 9269–9273. [Google Scholar] [CrossRef]
- Dinkins, M.B.; Enasko, J.; Hernandez, C.; Wang, G.; Kong, J.; Helwa, I.; Liu, Y.; Terry, A.V.; Bieberich, E. Neutral Sphingomyelinase-2 deficiency ameliorates Alzheimer’s disease pathology and improves cognition in the 5XFAD Mouse. J. Neurosci. 2016, 36, 8653–8667. [Google Scholar] [CrossRef] [Green Version]
- Dinkins, M.B.; Dasgupta, S.; Wang, G.; Zhu, G.; Bieberich, E. Exosome reduction in vivo is associated with lower amyloid plaque load in the 5XFAD mouse model of Alzheimer’s disease. Neurobiol. Aging 2014, 35, 1792–1800. [Google Scholar] [CrossRef] [Green Version]
- Zhou, X.; Zhang, W.; Yao, Q.; Zhang, H.; Dong, G.; Zhang, M.; Liu, Y.; Chen, J.-K.; Dong, Z. Exosome production and its regulation of EGFR during wound healing in renal tubular cells. Am. J. Physiol Ren. Physiol 2017, 312, F963–F970. [Google Scholar] [CrossRef]
- Catalano, M.; O’Driscoll, L. Inhibiting extracellular vesicles formation and release: A review of EV inhibitors. J. Extracell. Vesicles 2020, 9, 1703244. [Google Scholar] [CrossRef] [Green Version]
- Wu, X.; Zheng, T.; Zhang, B. Exosomes in Parkinson’s disease. Neurosci. Bull. 2017, 33, 331–338. [Google Scholar] [CrossRef]
- Matsumoto, J.; Stewart, T.; Sheng, L.; Li, N.; Bullock, K.; Song, N.; Shi, M.; Banks, W.A.; Zhang, J. Transmission of α-synuclein-containing erythrocyte-derived extracellular vesicles across the blood-brain barrier via adsorptive mediated transcytosis: Another mechanism for initiation and progression of Parkinson’s disease? Acta Neuropathol. Commun. 2017, 5, 71. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Peelaerts, W.; Bousset, L.; Van der Perren, A.; Moskalyuk, A.; Pulizzi, R.; Giugliano, M.; Van den Haute, C.; Melki, R.; Baekelandt, V. α-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 2015, 522, 340–344. [Google Scholar] [CrossRef] [PubMed]
- Meissner, W.G.; Frasier, M.; Gasser, T.; Goetz, C.G.; Lozano, A.; Piccini, P.; Obeso, J.A.; Rascol, O.; Schapira, A.; Voon, V.; et al. Priorities in Parkinson’s disease research. Nat. Rev. Drug Discov. 2011, 10, 377–393. [Google Scholar] [CrossRef] [PubMed]
- Haney, M.J.; Klyachko, N.L.; Zhao, Y.; Gupta, R.; Plotnikova, E.G.; He, Z.; Patel, T.; Piroyan, A.; Sokolsky, M.; Kabanov, A.V.; et al. Exosomes as drug delivery vehicles for Parkinson’s disease therapy. J. Control. Release 2015, 207, 18–30. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yu, H.; Sun, T.; An, J.; Wen, L.; Liu, F.; Bu, Z.; Cui, Y.; Feng, J. Potential roles of exosomes in Parkinson’s disease: From pathogenesis, diagnosis, and treatment to prognosis. Front. Cell Dev. Biol. 2020, 8, 86. [Google Scholar] [CrossRef] [Green Version]
- Alvarez-Erviti, L.; Seow, Y.; Yin, H.; Betts, C.; Lakhal, S.; Wood, M.J.A. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 2011, 29, 341–345. [Google Scholar] [CrossRef]
- Osorio-Querejeta, I.; Alberro, A.; Muñoz-Culla, M.; Mäger, I.; Otaegui, D. Therapeutic potential of extracellular vesicles for Demyelinating diseases; challenges and opportunities. Front. Mol. Neurosci. 2018, 11, 434. [Google Scholar] [CrossRef] [Green Version]
- Laso-García, F.; Ramos-Cejudo, J.; Carrillo-Salinas, F.J.; Otero-Ortega, L.; Feliú, A.; Gómez-de Frutos, M.; Mecha, M.; Díez-Tejedor, E.; Guaza, C.; Gutiérrez-Fernández, M. Therapeutic potential of extracellular vesicles derived from human mesenchymal stem cells in a model of progressive multiple sclerosis. PLoS ONE 2018, 13, e0202590. [Google Scholar] [CrossRef] [Green Version]
- Bhargava, P.; Nogueras-Ortiz, C.; Chawla, S.; Bæk, R.; Jørgensen, M.M.; Kapogiannis, D. Altered levels of toll-like receptors in circulating extracellular vesicles in multiple sclerosis. Cells 2019, 8, 1058. [Google Scholar] [CrossRef] [Green Version]
- Clifford, D.B.; Ances, B.M. HIV-associated neurocognitive disorder. Lancet Infect. Dis. 2013, 13, 976–986. [Google Scholar] [CrossRef] [Green Version]
- Mollace, V.; Nottet, H.S.L.M.; Clayette, P.; Turco, M.C.; Muscoli, C.; Salvemini, D.; Perno, C.F. Oxidative stress and neuroAIDS: Triggers, modulators and novel antioxidants. Trends Neurosci. 2001, 24, 411–416. [Google Scholar] [CrossRef]
- High, K.P.; Brennan-Ing, M.; Clifford, D.B.; Cohen, M.H.; Currier, J.; Deeks, S.G.; Deren, S.; Effros, R.B.; Gebo, K.; Goronzy, J.J.; et al. HIV and aging: State of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J. Acquir. Immune. Defic Syndr. 2012, 60 (Suppl. 1), S1–S18. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dewhurst, S.; Sakai, K.; Bresser, J.; Stevenson, M.; Evinger-Hodges, M.J.; Volsky, D.J. Persistent productive infection of human glial cells by human immunodeficiency virus (HIV) and by infectious molecular clones of HIV. J. Virol 1987, 61, 3774–3782. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Arakelyan, A.; Fitzgerald, W.; Zicari, S.; Vanpouille, C.; Margolis, L. Extracellular vesicles carry HIV Env and facilitate Hiv infection of human Lymphoid tissue. Sci. Rep. 2017, 7, 1695. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sami Saribas, A.; Cicalese, S.; Ahooyi, T.M.; Khalili, K.; Amini, S.; Sariyer, I.K. HIV-1 Nef is released in extracellular vesicles derived from astrocytes: Evidence for Nef-mediated neurotoxicity. Cell Death Dis. 2017, 8, e2542. [Google Scholar] [CrossRef] [Green Version]
- Rahimian, P.; He, J.J. Exosome-associated release, uptake, and neurotoxicity of HIV-1 Tat protein. J. Neurovirol. 2016, 22, 774–788. [Google Scholar] [CrossRef] [Green Version]
- Lenassi, M.; Cagney, G.; Liao, M.; Vaupotic, T.; Bartholomeeusen, K.; Cheng, Y.; Krogan, N.J.; Plemenitas, A.; Peterlin, B.M. HIV Nef is secreted in exosomes and triggers apoptosis in bystander CD4+ T cells. Traffic 2010, 11, 110–122. [Google Scholar] [CrossRef] [Green Version]
- Raymond, A.D.; Diaz, P.; Chevelon, S.; Agudelo, M.; Yndart-Arias, A.; Ding, H.; Kaushik, A.; Jayant, R.D.; Nikkhah-Moshaie, R.; Roy, U.; et al. Microglia-derived HIV Nef+ exosome impairment of the blood-brain barrier is treatable by nanomedicine-based delivery of Nef peptides. J. Neurovirol. 2016, 22, 129–139. [Google Scholar] [CrossRef]
- Ali, S.A.; Huang, M.-B.; Campbell, P.E.; Roth, W.W.; Campbell, T.; Khan, M.; Newman, G.; Villinger, F.; Powell, M.D.; Bond, V.C. Genetic characterization of HIV type 1 Nef-induced vesicle secretion. Aids Res. Hum. Retrovir. 2010, 26, 173–192. [Google Scholar] [CrossRef]
- Arenaccio, C.; Anticoli, S.; Manfredi, F.; Chiozzini, C.; Olivetta, E.; Federico, M. Latent HIV-1 is activated by exosomes from cells infected with either replication-competent or defective HIV-1. Retrovirology 2015, 12, 87. [Google Scholar] [CrossRef] [Green Version]
- Rozmyslowicz, T.; Majka, M.; Kijowski, J.; Murphy, S.L.; Conover, D.O.; Poncz, M.; Ratajczak, J.; Gaulton, G.N.; Ratajczak, M.Z. Platelet- and megakaryocyte-derived microparticles transfer CXCR4 receptor to CXCR4-null cells and make them susceptible to infection by X4-HIV. AIDS 2003, 17, 33–42. [Google Scholar] [CrossRef] [PubMed]
- Mack, M.; Kleinschmidt, A.; Brühl, H.; Klier, C.; Nelson, P.J.; Cihak, J.; Plachý, J.; Stangassinger, M.; Erfle, V.; Schlöndorff, D. Transfer of the chemokine receptor CCR5 between cells by membrane-derived microparticles: A mechanism for cellular human immunodeficiency virus 1 infection. Nat. Med. 2000, 6, 769–775. [Google Scholar] [CrossRef] [PubMed]
- Gisslén, M.; Krut, J.; Andreasson, U.; Blennow, K.; Cinque, P.; Brew, B.J.; Spudich, S.; Hagberg, L.; Rosengren, L.; Price, R.W.; et al. Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. Bmc Neurol. 2009, 9, 63. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Iwata, N. Metabolic regulation of brain Abeta by Neprilysin. Science 2001, 292, 1550–1552. [Google Scholar] [CrossRef]
- Giunta, B.; Zhou, Y.; Hou, H.; Rrapo, E.; Fernandez, F.; Tan, J. HIV-1 TAT inhibits microglial phagocytosis of Abeta peptide. Int. J. Clin. Exp. Pathol. 2008, 1, 260–275. [Google Scholar]
- Rempel, H.C.; Pulliam, L. HIV-1 Tat inhibits neprilysin and elevates amyloid beta. AIDS 2005, 19, 127–135. [Google Scholar] [CrossRef]
- Shahjin, F.; Chand, S.; Yelamanchili, S.V. Extracellular vesicles as drug delivery vehicles to the Central Nervous System. J. Neuroimmune Pharm. 2019. [Google Scholar] [CrossRef]
- Soliman, M.L.; Geiger, J.D.; Chen, X. Caffeine blocks HIV-1 Tat-induced Amyloid Beta production and Tau Phosphorylation. J. Neuroimmune Pharm. 2017, 12, 163–170. [Google Scholar] [CrossRef] [Green Version]
- Eskelinen, M.H.; Kivipelto, M. Caffeine as a protective factor in dementia and Alzheimer’s disease. J. Alzheimers Dis. 2010, 20 (Suppl. 1), S167–S174. [Google Scholar] [CrossRef] [Green Version]
- Majumder, S.; Richardson, A.; Strong, R.; Oddo, S. Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits. PLoS ONE 2011, 6, e25416. [Google Scholar] [CrossRef] [Green Version]
- Sun, B.; Dalvi, P.; Abadjian, L.; Tang, N.; Pulliam, L. Blood neuron-derived exosomes as biomarkers of cognitive impairment in HIV. AIDS 2017, 31, F9–F17. [Google Scholar] [CrossRef]
- Guedes, V.A.; Devoto, C.; Leete, J.; Sass, D.; Acott, J.D.; Mithani, S.; Gill, J.M. Extracellular vesicle proteins and MicroRNAs as biomarkers for traumatic brain injury. Front. Neurol. 2020, 11, 663. [Google Scholar] [CrossRef]
- Ko, J.; Hemphill, M.; Yang, Z.; Sewell, E.; Na, Y.J.; Sandsmark, D.K.; Haber, M.; Fisher, S.A.; Torre, E.A.; Svane, K.C.; et al. Diagnosis of traumatic brain injury using miRNA signatures in nanomagnetically isolated brain-derived extracellular vesicles. Lab Chip 2018, 18, 3617–3630. [Google Scholar] [CrossRef]
- Gill, J.; Mustapic, M.; Diaz-Arrastia, R.; Lange, R.; Gulyani, S.; Diehl, T.; Motamedi, V.; Osier, N.; Stern, R.A.; Kapogiannis, D. Higher exosomal tau, amyloid-beta 42 and IL-10 are associated with mild TBIs and chronic symptoms in military personnel. Brain Inj. 2018, 32, 1277–1284. [Google Scholar] [CrossRef]
- Loane, D.J.; Kumar, A.; Stoica, B.A.; Cabatbat, R.; Faden, A.I. Progressive neurodegeneration after experimental brain trauma: Association with chronic microglial activation. J. Neuropathol. Exp. Neurol. 2014, 73, 14–29. [Google Scholar] [CrossRef] [Green Version]
- Kumar, A.; Henry, R.J.; Stoica, B.A.; Loane, D.J.; Abulwerdi, G.; Bhat, S.A.; Faden, A.I. Neutral Sphingomyelinase inhibition alleviates LPS-induced microglia activation and neuroinflammation after experimental traumatic brain injury. J. Pharm. Exp. 2019, 368, 338–352. [Google Scholar] [CrossRef] [Green Version]
- Aghagoli, G.; Gallo Marin, B.; Katchur, N.J.; Chaves-Sell, F.; Asaad, W.F.; Murphy, S.A. Neurological involvement in COVID-19 and potential mechanisms: A review. Neurocritical Care 2020. [Google Scholar] [CrossRef]
- Hassanpour, M.; Rezaie, J.; Nouri, M.; Panahi, Y. The role of extracellular vesicles in COVID-19 virus infection. Infect. Genet. Evol. J. Mol. Epidemiol. Evol. Genet. Infect. Dis. 2020, 85, 104422. [Google Scholar] [CrossRef]
- Tian, J.; Casella, G.; Zhang, Y.; Rostami, A.; Li, X. Potential roles of extracellular vesicles in the pathophysiology, diagnosis, and treatment of autoimmune diseases. Int. J. Biol. Sci. 2020, 16, 620–632. [Google Scholar] [CrossRef] [Green Version]
- György, B.; Hung, M.E.; Breakefield, X.O.; Leonard, J.N. Therapeutic applications of extracellular vesicles: Clinical promise and open questions. Annu. Rev. Pharm. Toxicol. 2015, 55, 439–464. [Google Scholar] [CrossRef] [Green Version]
- Lener, T.; Gimona, M.; Aigner, L.; Börger, V.; Buzas, E.; Camussi, G.; Chaput, N.; Chatterjee, D.; Court, F.A.; Portillo, H.A.d.; et al. Applying extracellular vesicles based therapeutics in clinical trials—An ISEV position paper. J. Extracell. Vesicles 2015, 4, 30087. [Google Scholar] [CrossRef]
- Vázquez-Ríos, A.J.; Molina-Crespo, Á.; Bouzo, B.L.; López-López, R.; Moreno-Bueno, G.; de la Fuente, M. Exosome-mimetic nanoplatforms for targeted cancer drug delivery. Nanobiotechnology 2019, 17, 85. [Google Scholar] [CrossRef] [Green Version]
- Munagala, R.; Aqil, F.; Jeyabalan, J.; Gupta, R.C. Bovine milk-derived exosomes for drug delivery. Cancer Lett. 2016, 371, 48–61. [Google Scholar] [CrossRef] [Green Version]
- Yang, T.; Martin, P.; Fogarty, B.; Brown, A.; Schurman, K.; Phipps, R.; Yin, V.P.; Lockman, P.; Bai, S. Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in Danio rerio. Pharm. Res. 2015, 32, 2003–2014. [Google Scholar] [CrossRef]
- Aqil, F.; Kausar, H.; Agrawal, A.K.; Jeyabalan, J.; Kyakulaga, A.-H.; Munagala, R.; Gupta, R. Exosomal formulation enhances therapeutic response of celastrol against lung cancer. Exp. Mol. Pathol. 2016, 101, 12–21. [Google Scholar] [CrossRef]
- Didiot, M.-C.; Hall, L.M.; Coles, A.H.; Haraszti, R.A.; Godinho, B.M.; Chase, K.; Sapp, E.; Ly, S.; Alterman, J.F.; Hassler, M.R.; et al. Exosome-mediated delivery of hydrophobically modified siRNA for huntingtin mRNA silencing. Mol. Ther. 2016, 24, 1836–1847. [Google Scholar] [CrossRef] [Green Version]
- Shtam, T.A.; Kovalev, R.A.; Varfolomeeva, E.Y.; Makarov, E.M.; Kil, Y.V.; Filatov, M.V. Exosomes are natural carriers of exogenous siRNA to human cells in vitro. Cell Commun. Signal. 2013, 11, 88. [Google Scholar] [CrossRef] [Green Version]
- Ohno, S.; Takanashi, M.; Sudo, K.; Ueda, S.; Ishikawa, A.; Matsuyama, N.; Fujita, K.; Mizutani, T.; Ohgi, T.; Ochiya, T.; et al. Systemically injected exosomes targeted to EGFR deliver antitumor MicroRNA to breast cancer cells. Mol. Ther. 2013, 21, 185–191. [Google Scholar] [CrossRef] [Green Version]
- Barba, A.A.; Bochicchio, S.; Dalmoro, A.; Lamberti, G. Lipid Delivery Systems for Nucleic-Acid-Based-Drugs: From Production to Clinical Applications. Pharmaceutics 2019, 11, 360. [Google Scholar] [CrossRef] [Green Version]
- Xu, L.; Anchordoquy, T. Drug delivery trends in clinical trials and translational medicine: Challenges and opportunities in the delivery of nucleic acid-based therapeutics. J. Pharm. Sci. 2011, 100, 38–52. [Google Scholar] [CrossRef] [Green Version]
- Roberts, T.C.; Langer, R.; Wood, M.J.A. Advances in oligonucleotide drug delivery. Nat. Rev. Drug Discov. 2020, 19, 673–694. [Google Scholar] [CrossRef]
- Xin, H.; Li, Y.; Cui, Y.; Yang, J.J.; Zhang, Z.G.; Chopp, M. Systemic Administration of Exosomes Released from Mesenchymal Stromal Cells Promote Functional Recovery and Neurovascular Plasticity after Stroke in Rats. J. Cereb. Blood Flow Metab. 2013, 33, 1711–1715. [Google Scholar] [CrossRef] [Green Version]
- Raisi, A.; Azizi, S.; Delirezh, N.; Heshmatian, B.; Farshid, A.A.; Amini, K. The Mesenchymal Stem Cell-Derived Microvesicles Enhance Sciatic Nerve Regeneration in Rat: A Novel Approach in Peripheral Nerve Cell Therapy. J. Trauma Acute Care Surg. 2014, 76, 991–997. [Google Scholar] [CrossRef] [Green Version]
- Kordelas, L.; Rebmann, V.; Ludwig, A.-K.; Radtke, S.; Ruesing, J.; Doeppner, T.R.; Epple, M.; Horn, P.A.; Beelen, D.W.; Giebel, B. MSC-Derived Exosomes: A Novel Tool to Treat Therapy-Refractory Graft-versus-Host Disease. Leukemia 2014, 28, 970–973. [Google Scholar] [CrossRef]
- Ophelders, D.R.M.G.; Wolfs, T.G.A.M.; Jellema, R.K.; Zwanenburg, A.; Andriessen, P.; Delhaas, T.; Ludwig, A.-K.; Radtke, S.; Peters, V.; Janssen, L.; et al. Mesenchymal Stromal Cell-Derived Extracellular Vesicles Protect the Fetal Brain After Hypoxia-Ischemia. Stem Cells Transl. Med. 2016, 5, 754–763. [Google Scholar] [CrossRef] [Green Version]
- Sun, D.; Zhuang, X.; Xiang, X.; Liu, Y.; Zhang, S.; Liu, C.; Barnes, S.; Grizzle, W.; Miller, D.; Zhang, H.-G. A novel nanoparticle drug delivery system: The anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol. Ther. 2010, 18, 1606–1614. [Google Scholar] [CrossRef]
- Ravindran, J.; Prasad, S.; Aggarwal, B.B. Curcumin and cancer cells: How many ways can curry kill tumor cells selectively? Aaps J. 2009, 11, 495–510. [Google Scholar] [CrossRef]
- Usman, W.M.; Pham, T.C.; Kwok, Y.Y.; Vu, L.T.; Ma, V.; Peng, B.; Chan, Y.S.; Wei, L.; Chin, S.M.; Azad, A.; et al. Efficient RNA drug delivery using red blood cell extracellular vesicles. Nat. Commun. 2018, 9, 2359. [Google Scholar] [CrossRef]
- Cooper, J.M.; Wiklander, P.B.O.; Nordin, J.Z.; Al-Shawi, R.; Wood, M.J.; Vithlani, M.; Schapira, A.H.V.; Simons, J.P.; El-Andaloussi, S.; Alvarez-Erviti, L. Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice: siRNA-EXOSOME decreased Alpha-Synuclein aggregates. Mov. Disord. 2014, 29, 1476–1485. [Google Scholar] [CrossRef] [Green Version]
- Gerth, K.; Kodidela, S.; Mahon, M.; Haque, S.; Verma, N.; Kumar, S. Circulating extracellular vesicles containing xenobiotic metabolizing CYP enzymes and their potential roles in extrahepatic cells via cell-cell interactions. Int. J. Mol. Sci. 2019, 20, 6178. [Google Scholar] [CrossRef] [Green Version]
- Kumar, S.; Sinha, N.; Gerth, K.A.; Rahman, M.A.; Yallapu, M.M.; Midde, N.M. Specific packaging and circulation of cytochromes P450, especially 2E1 isozyme, in human plasma exosomes and their implications in cellular communications. Biochem. Biophys. Res. Commun. 2017, 491, 675–680. [Google Scholar] [CrossRef]
- Kodidela, S.; Gerth, K.; Sinha, N.; Kumar, A.; Kumar, P.; Kumar, S. Circulatory Astrocyte and neuronal EVs as potential biomarkers of neurological dysfunction in HIV-infected subjects and alcohol/tobacco users. Diagnostics 2020, 10, 349. [Google Scholar] [CrossRef]
- Gong, Y.; Rao, P.S.S.; Sinha, N.; Ranjit, S.; Cory, T.J.; Kumar, S. The role of cytochrome P450 2E1 on ethanol-mediated oxidative stress and HIV replication in human monocyte-derived macrophages. Biochem. Biophys. Rep. 2019, 17, 65–70. [Google Scholar] [CrossRef]
- Haque, S.; Sinha, N.; Ranjit, S.; Midde, N.M.; Kashanchi, F.; Kumar, S. Monocyte-derived exosomes upon exposure to cigarette smoke condensate alter their characteristics and show protective effect against cytotoxicity and HIV-1 replication. Sci. Rep. 2017, 7, 16120. [Google Scholar] [CrossRef] [Green Version]
- Tseng, A.; Hughes, C.A.; Wu, J.; Seet, J.; Phillips, E.J. Cobicistat versus ritonavir: Similar pharmacokinetic enhancers but some important differences. Ann. Pharm. 2017, 51, 1008–1022. [Google Scholar] [CrossRef] [Green Version]
- Palleria, C.; Di Paolo, A.; Giofrè, C.; Caglioti, C.; Leuzzi, G.; Siniscalchi, A.; De Sarro, G.; Gallelli, L. Pharmacokinetic drug-drug interaction and their implication in clinical management. J. Res. Med. Sci. 2013, 18, 601–610. [Google Scholar]
- Charoenviriyakul, C.; Takahashi, Y.; Morishita, M.; Matsumoto, A.; Nishikawa, M.; Takakura, Y. Cell type-specific and common characteristics of exosomes derived from mouse cell lines: Yield, physicochemical properties, and pharmacokinetics. Eur. J. Pharm. Sci. 2017, 96, 316–322. [Google Scholar] [CrossRef]
- Wen, S.; Dooner, M.; Papa, E.; Del Tatto, M.; Pereira, M.; Borgovan, T.; Cheng, Y.; Goldberg, L.; Liang, O.; Camussi, G.; et al. Biodistribution of Mesenchymal stem cell-derived extracellular vesicles in a radiation injury bone marrow murine model. Int. J. Mol. Sci. 2019, 20, 5468. [Google Scholar] [CrossRef] [Green Version]
- Wiklander, O.P.B.; Nordin, J.Z.; O’Loughlin, A.; Gustafsson, Y.; Corso, G.; Mäger, I.; Vader, P.; Lee, Y.; Sork, H.; Seow, Y.; et al. Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting. J. Extracell. Vesicles 2015, 4, 26316. [Google Scholar] [CrossRef] [Green Version]
- Lievens, J.; Snoeys, J.; Vekemans, K.; Van Linthout, S.; de Zanger, R.; Collen, D.; Wisse, E.; De Geest, B. The size of sinusoidal fenestrae is a critical determinant of hepatocyte transduction after adenoviral gene transfer. Gene Ther. 2004, 11, 1523–1531. [Google Scholar] [CrossRef] [Green Version]
- Imai, T.; Takahashi, Y.; Nishikawa, M.; Kato, K.; Morishita, M.; Yamashita, T.; Matsumoto, A.; Charoenviriyakul, C.; Takakura, Y. Macrophage-dependent clearance of systemically administered B16BL6-derived exosomes from the blood circulation in mice. J. Extracell. Vesicles 2015, 4, 26238. [Google Scholar] [CrossRef]
- Morishita, M.; Takahashi, Y.; Nishikawa, M.; Takakura, Y. Pharmacokinetics of Exosomes-an important factor for elucidating the biological roles of Exosomes and for the development of exosome-based therapeutics. J. Pharm. Sci. 2017, 106, 2265–2269. [Google Scholar] [CrossRef] [Green Version]
- Betzer, O.; Perets, N.; Angel, A.; Motiei, M.; Sadan, T.; Yadid, G.; Offen, D.; Popovtzer, R. In vivo neuroimaging of exosomes using gold nanoparticles. ACS Nano 2017, 11, 10883–10893. [Google Scholar] [CrossRef]
- Arntz, O.J.; Pieters, B.C.H.; Broeren, M.G.A.; Bennink, M.B.; De Vries, M.; Van Lent, P.L.E.M.; Koenders, M.I.; Van den Berg, W.B.; Van der Kraan, P.M.; Van de Loo, F.A.J.; et al. Oral administration of bovine milk derived extracellular vesicles attenuates arthritis in two mouse models. Mol. Nutr. Food Res. 2015, 59, 1701–1712. [Google Scholar] [CrossRef]
- Ha, D.; Yang, N.; Nadithe, V. Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: Current perspectives and future challenges. Acta Pharm. Sin. B 2016, 6, 287–296. [Google Scholar] [CrossRef] [Green Version]
- Kim, M.S.; Haney, M.J.; Zhao, Y.; Mahajan, V.; Deygen, I.; Klyachko, N.L.; Inskoe, E.; Piroyan, A.; Sokolsky, M.; Okolie, O.; et al. Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. Nanomedicine 2016, 12, 655–664. [Google Scholar] [CrossRef] [Green Version]
- Akuma, P.; Okagu, O.D.; Udenigwe, C.C. Naturally occurring exosome vesicles as potential delivery vehicle for bioactive compounds. Front. Sustain. Food Syst. 2019, 3, 23. [Google Scholar] [CrossRef]
- Barile, L.; Vassalli, G. Exosomes: Therapy delivery tools and biomarkers of diseases. Pharmacol. Ther. 2017, 174, 63–78. [Google Scholar] [CrossRef] [Green Version]
- Jiang, X.-C.; Gao, J.-Q. Exosomes as novel bio-carriers for gene and drug delivery. Int. J. Pharm. 2017, 521, 167–175. [Google Scholar] [CrossRef]
- He, C.; Zheng, S.; Luo, Y.; Wang, B. Exosome theranostics: Biology and translational medicine. Theranostics 2018, 8, 237–255. [Google Scholar] [CrossRef]
- Lässer, C. Exosomes in diagnostic and therapeutic applications: Biomarker, vaccine and RNA interference delivery vehicle. Expert Opin. Biol. 2015, 15, 103–117. [Google Scholar] [CrossRef] [PubMed]
- El Andaloussi, S.; Mäger, I.; Breakefield, X.O.; Wood, M.J.A. Extracellular vesicles: Biology and emerging therapeutic opportunities. Nat. Rev. Drug Discov. 2013, 12, 347–357. [Google Scholar] [CrossRef] [PubMed]
- Cossetti, C.; Iraci, N.; Mercer, T.R.; Leonardi, T.; Alpi, E.; Drago, D.; Alfaro-Cervello, C.; Saini, H.K.; Davis, M.P.; Schaeffer, J.; et al. Extracellular vesicles from neural stem cells transfer IFN-γ via Ifngr1 to activate Stat1 signaling in target cells. Mol. Cell 2014, 56, 193–204. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Smyth, T.; Kullberg, M.; Malik, N.; Smith-Jones, P.; Graner, M.W.; Anchordoquy, T.J. Biodistribution and delivery efficiency of unmodified tumor-derived exosomes. J. Control. Release 2015, 199, 145–155. [Google Scholar] [CrossRef] [Green Version]
- Pucci, F.; Garris, C.; Lai, C.P.; Newton, A.; Pfirschke, C.; Engblom, C.; Alvarez, D.; Sprachman, M.; Evavold, C.; Magnuson, A.; et al. SCS macrophages suppress melanoma by restricting tumor-derived vesicle-B cell interactions. Science 2016, 352, 242–246. [Google Scholar] [CrossRef] [Green Version]
- Clayton, A.; Al-Taei, S.; Webber, J.; Mason, M.D.; Tabi, Z. Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production. J. Immunol. 2011, 187, 676–683. [Google Scholar] [CrossRef]
Material Classification | Name | Structure | References |
---|---|---|---|
Metal Elemental | Gold Nanoparticles (AuNPs) | Nanosphere | [12,13] |
Metal Elemental | Silver Nanoparticles (AgNPs) | Nanosphere | [14] |
Metal Oxide | Iron Oxide Nanoparticles | Nanosphere | [15,16] |
Metal Oxide | Cerium Oxide Nanoparticles | Nanosphere | [17,18] |
Metal Oxide | Zinc Oxide Nanoparticles | Nanosphere | [19,20] |
Inorganic Compound | Quantum Dots | Nano Tube | [21,22] |
Metalloid Elemental | Silica Nanoparticles (SiNPs) | Nanosphere | [23,24,25] |
Lipid | Liposomes | Nanosphere with Bilayer Surface | [26,27] |
Lipid | Micelles | Nanosphere | [28] |
Lipid | Solid Lipid Nanoparticles (SLN) | Nanosphere with Monolayer Surface | [29] |
Lipid | Extracellular Vesicles (EVs) | Nanosphere with Bilayer Surface | [30] |
Polymer | Polylactic Acid (PLA) | Porous Nanosphere | [31] |
Polymer | Poly Lactic-co-Glycolic Acid (PLGA) | Porous Nanosphere | [5,6] |
Polymer | Polyethylene Glycol (PEG) | Porous Nanosphere | [32] |
Polymer | Hydrogel | Porous Matrix | [10,11] |
Loaded Drug Type | Targeted Disease Cells | Drug Delivery Method | Clinical Trial Phase | Reference |
---|---|---|---|---|
miRNA (nucleic acid drug type) | EGFR-expressing breast cancer cells | Exosome surface modification w/GE11 peptides | unspecified | [150] |
Curcumin (anti-inflammatory) | Monocyte-derived myeloid cells associated with inflammation related autoimmune diseases | i.p. injection of exosomal curcumin into mice | unspecified | [158] |
Cas9 mRNA and antisense oligonucleotides | Leukemia cells and breast cancer cells | in vivo delivery of ASO-loaded EVs via i.p. injection in mice | unspecified | [160] |
siRNA molecules | Cells affected by AD (neurons, microglia, oligodendrocytes) | Mice administered i.v. injection of RVG-targeted exosomes | unspecified | [108] |
Catalase (antioxidant enzyme) | Cells of neurovascular unit affected by PD (neurons, astrocytes, and brain microvessel endothelial cells) | Intranasal administration of catalase-loaded exosomes | unspecified | [106] |
siRNA molecules | α-Syn aggregates of Lewy bodies associated with Parkinson’s Disease | Peripheral injection of siRNA modified exosomes in the brain of mice | unspecified | [161] |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kumar, A.; Zhou, L.; Zhi, K.; Raji, B.; Pernell, S.; Tadrous, E.; Kodidela, S.; Nookala, A.; Kochat, H.; Kumar, S. Challenges in Biomaterial-Based Drug Delivery Approach for the Treatment of Neurodegenerative Diseases: Opportunities for Extracellular Vesicles. Int. J. Mol. Sci. 2021, 22, 138. https://doi.org/10.3390/ijms22010138
Kumar A, Zhou L, Zhi K, Raji B, Pernell S, Tadrous E, Kodidela S, Nookala A, Kochat H, Kumar S. Challenges in Biomaterial-Based Drug Delivery Approach for the Treatment of Neurodegenerative Diseases: Opportunities for Extracellular Vesicles. International Journal of Molecular Sciences. 2021; 22(1):138. https://doi.org/10.3390/ijms22010138
Chicago/Turabian StyleKumar, Asit, Lina Zhou, Kaining Zhi, Babatunde Raji, Shelby Pernell, Erene Tadrous, Sunitha Kodidela, Anantha Nookala, Harry Kochat, and Santosh Kumar. 2021. "Challenges in Biomaterial-Based Drug Delivery Approach for the Treatment of Neurodegenerative Diseases: Opportunities for Extracellular Vesicles" International Journal of Molecular Sciences 22, no. 1: 138. https://doi.org/10.3390/ijms22010138